We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers can reduce their liability risks and avoid other pitfalls associated with establishing clinical trial databases by using a review team to ensure trial results are complete and free of promotional claims, says a GlaxoSmithKline (GSK) executive.